Apparatus

Carvykti gains new ground and competes with its "predecessor"!

Was the omission of key data intentional or unintentional?

Under the terms of the collaboration agreement, GenKOre will receive up to US$300 million, including upfront fees, fees for exercising its option, and milestone payments for successfully reaching development and commercialisation milestones against two in vivo disease targets.

Ibuprofen belongs to antipyretic and analgesic, not cold medicine.

Accelerating and simplifying the development and manufacturing process of cell and gene therapies.

Stroke is the main cause of disability in Americans. More than 6.5 million Americans survive stroke every year, and most of them cannot fully recover their walking ability. Experts said that because of the difficulty in walking, these patients would not even go out to the store to buy things, but they were inactive for a long time, which led to other health problems and a spiral decline in their quality of life.

The dental profession can use these tools as a guide to improve the sustainability of their working environment and to recognise their efforts by tracking progress.

The Fraunhofer Institute in Germany has now developed two techniques that could make testing faster and cheaper.

Biopharmaceutical company Airway has announced that the first patient will be administered AT-100 (rhSP-D) in a phase 1b randomised trial to prevent the risk of bronchopulmonary dysplasia (BPD) in very preterm infants. The novel prophylactic AT-100 reduces the incidence and severity of the severe respiratory disease BPD and may improve the prognosis of very preterm infants.

The global ADC drug market will be approximately $5.2 billion by 2021